PROTEIN ANTIBODY & VACCINES WORLD CONGRESS 2024 EUROPE

London, United Kingdom
  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

Vaccines & Immunogenicity World Congress 2023 Europe

Full Program Available Shortly 

Dear Colleagues,

Paradigm Global Events is proud to present its Vaccines & Immunogenicity World Congress 2023 Europe. Progress in virology, genetics, synthetic biology, and biotechnology has provided a new set of tools to approach current-day vaccinology, while increased understanding of human immunity and microbes has catalyzed unprecedented advances that can be adopted to improve public health. Despite continuing challenges, the collective effort of governments and nonprofit organizations to expand the utilization of effective vaccines throughout the world has grown.

 

We look forward to meeting you at the Congress!

Sincerely yours,

Jocelyn Raguindin
Conference Director
Paradigm Global Events

GAIN LATEST INSIGHTS ON:

In the upcoming 2023 Vaccine Congress, dynamic approach to key trends, methodologies and insights on new vaccine platforms for cancer and emerging diseases, manufacturing trends, and regulatory compliance is anticipated. Gain latest insights on:

WHO SHOULD ATTEND?

Network with cancer geneticists, cancer biologists, experts in cancer antigen presentation, tumor immunologists, vaccinologists, senior VPs, Heads, Directors and Managers of leading biopharmaceutical and biotech companies whose responsibilities include manufacturing, research and development, regulatory and marketing, government and non-
government vaccine leads: 

0 +
speakers
0
days Congress
0 +
Presentation
0 +
Attendees

Key Industry Expert Speakers

2023 Speakers - will be uploaded shortly.

Available Shortly

Senior Representative

Coming Soon

Available Shortly

Senior Representative

Coming Soon

Available Shortly

Senior Representative

Coming Soon

Available Shortly

Senior Representative

Coming Soon

Available Shortly

Senior Representative

Coming Soon

Available Shortly

Senior Representative

Coming Soon

Schedule

Content Rich Program Agenda!  Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.

  • Novel vaccination approaches based on rational design of B­ and T­cell epitopes
  • Progress on using recombinant DNA technology, advanced cell­culture technique, immunoinformatics and rational design of immunogens for vaccine
    development

VACCINE TECHNOLOGY AND PRODUCTION

  • Impact of different inactivation and splitting procedures on vaccine composition, stability and recovery to support transfer of process technology
  • Bioreactors for high cell density and continuous multi-stage cultivations as new options for process intensification in cell culture-based viral vaccine production
  • High cell density and continuous multi-stage cultivations as options for process intensification in cell culture-based viral vaccine production
  • Recent developments in establishing new designed cell lines, better host cell metabolism, advances in media design, and the use of mathematical models for process optimization
  • Replication-deficient adenoviruses as potent vaccine development platforms for human candidate vaccines
  • Cellular targets for improved manufacturing of virus-based biopharmaceuticals in animal cells
  • Clarification of vaccines as critical step for product recovery and subsequent downstream purification
  • Comprehensive view on different membrane based technologies and their application in vaccine clarification, challenges and best practice

REGULATORY COMPLIANCE AND CLINICAL TRIALS

  • Continued evolution of safety evaluation processes that keep pace with advances in vaccine technology
  • Regulatory aspects relevant to adjuvanted vaccines
  • Summary of lessons learned from completed HIV/AIDS vaccine efficacy trials relevant to regulatory evaluation of clinical trial applications for vaccines in development
  • Challenges regulators face when reviewing clinical trial applications
  • Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines
  • Combinations of immuno-stimulatory or immuno-modulatory adjuvants for the development of novel adjuvants for cancer immunotherapy

VACCINES AGAINST CANCER AND EMERGING DISEASES

  • Oncolytic virotherapy and immune checkpoint blockade agents to enhance the anti tumor response
  • Adapting dendritic cell-based vaccine for pancreatic cancer
  • Novel vaccine designs that employ strategies to prevent HIV acquisition and development of therapeutic vaccine
  • Dendritic cell activation and HIV vaccine effectiveness enhanced through nanoparticle vaccination
  • Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine
  • Development of therapeutic antibodies against dengue virus

VACCINES AGAINST CANCER AND EMERGING DISEASES

  • B and T cell epitope-based peptides from conserved and whole protein sequences of Ebola virus as vaccine targets
  • Identification of cell-targeting antibodies in immunity to Ebola
  • Targeting conserved B­ and T­cell epitopes for developing broadly protective or “universal” influenza virus vaccines 
  • Developing quadrivalent virus like particle influenza vaccine from plants
  • Status of vaccine research and development of vaccines for tuberculosis
  • Complement component 3 as new paradigm in tuberculosis vaccine
  • A retrospective analysis of the Alzheimer's disease vaccine progress
  • Focus on amyloid-β, α-synuclein, and tau for the treatment of neurodegenerative disorders

Vaccines & Immunogenicity World Congress Europe

Newsletter Sign Up

No Spam - You will only receive relevant information on Real-World Evidence, and event updates

Delegate Tickets

Group Discounts Are Also Available

Advocates / Patient / Non Profit

Full Price
£799
  • Full Access - 2 Day Conference
  • All Day Refreshments & Lunches
  • Conference Documentations
  • Networking Drinks Reception

Standard Registration Rate

Full Price
£1299
  • Full Access - 2 Day Conference
  • All Day Refreshments & Lunches
  • Conference Documentations
  • Networking Drinks Reception

Testimonials

what people say

Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.
Salvador Berrios
ERP/ CRM / Product Configurator Manager
The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations
Thomas Martin
Associate Vice President, VCGA - Quintiles
I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.
Adriana E. Manzi
PhD, Managing Director, Atheln, Inc

Previous events

Book Your Place Now! 

Register To Attend Now!

Take Advantage of the Super Early Bird Discount. Group Discounts Also Available. 

Location

Scroll to Top